Release

Today’s Research Reports on Trending Tickers: Bellicum Pharmaceuticals and Endocyte

U.S. market slumped Tuesday as technology stocks fell amid concerns of growing trade tensions between the U.S. and China. The Dow Jones Industrial Average declined 0.68 percent to close at 25,007.03, while the S&P 500 Index dipped 0.64 percent to close at 2,765.31. The tech-heavy Nasdaq Composite Index dropped 1.02 percent to close at 7,511.01. Semiconductor stocks were some of the worst performers as The VanEck Vectors Semiconductor ETF fell 1.4 percent.

"The worry is with the Tillerson ouster and Broadcom blockage from the Trump administration that this will add fuel to the fire in a battle versus China on the horizon over the coming 12 to 18 months," said Dan Ives, head of technology research at GBH Insights, in a note, according to CNBC.

RDI Initiates Coverage on:

Bellicum Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=BLCM

Endocyte, Inc.
https://rdinvesting.com/news/?ticker=ECYT

Bellicum Pharmaceuticals’ stock edged 0.62% higher Tuesday, to close the day at $8.08. The stock recorded a trading volume of 1,201,451 shares, which was above its three months average volume of 851,135 shares. In the last year, Bellicum Pharmaceuticals’ shares have traded in a range of 5.02 – 15.55. The share price has gained 60.96% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $7.01 is below its 200-day moving average of $9.19. Shares of Bellicum Pharmaceuticals have gained roughly 40.03 percent in the past month and are down 3.92 percent year-to-date.

Access RDI’s Bellicum Pharmaceuticals, Inc. Research Report at:  
https://rdinvesting.com/news/?ticker=BLCM

On Tuesday, shares of Endocyte recorded a trading volume of 12,265,712 shares, which was above the three months average volume of 1,871,163 shares. The stock ended the day 22.54% higher at 10.82. The share price has gained 824.79% from its 52 week low with a 52 week trading range of 1.17 – 11.54. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $4.58 is greater than its 200-day moving average of $4.06. Shares of Endocyte have gained roughly 249.03 percent in the past month and are up 152.8 percent year-to-date.

Access RDI’s Endocyte, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ECYT

Our Actionable Research on Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) and Endocyte, Inc. (NASDAQ:ECYT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

[email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.